PR 2023

BIOCORP obtains 510(k) FDA clearance for SoloSmart®, Sanofi’s smart cap for disposable insulin pens.

240125 PR_BIOCORP

BIOCORP reports half-year results as of June 30, 2023

230904 PR_BIOCORP_H1 results

Completion of Novo Nordisk’s acquisition of a controlling stake in BIOCORP

230804 PR_BIOCORP

Signing of the definitive agreements in connection with the acquisition by NOVO NORDISK of a controlling stake in BIOCORP

230619 PR BIOCORP

Novo Nordisk enters into exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares.

230605 PR BIOCORP

BIOCORP: Full-Year 2022 financial results and outlook for 2023

230329 PR BIOCORP

BIOCORP signs with HRA Pharma for the development of a medical device innovation

230314 PR BIOCORP

BIOCORP completes a €2.5 million convertible bond issue subscribed by funds managed by Vatel Capital

230102 PR BIOCORP